The purpose is to determine whether adding this chemotherapy improves the length of time without cancer recurrence compared with observation alone. After random assignment, participants receive either the chemotherapy regimen or only active surveillance, meaning they are monitored regularly with visits and tests but receive no additional treatment. The study follows participants for several years, recording any return of disease, side effects, overall survival, and quality of life through questionnaires.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

The purpose of this study is to find out how long people live without their cancer getting worse when treated with zanzalintinib compared to everolimus. The study will also look at how many people respond to the treatment, meaning their tumors shrink or disappear, and how long people live overall. Participants will be randomly assigned to receive either zanzalintinib or everolimus, and both the participants and their doctors will know which treatment they are receiving. During the study, participants will have regular check-ups and imaging scans to monitor their cancer and overall health.

Participants will continue taking their assigned medicine as long as it is helping them and not causing unacceptable side effects. The study will collect information about how well each medicine works and what side effects occur. Blood tests and other medical assessments will be done regularly to monitor safety. Some participants may continue taking other hormone-related medicines they were already using if their tumor produces hormones that cause symptoms. The study aims to help doctors understand which treatment option may work better for people with this type of cancer who have already received some previous treatment.

The purpose of this study is to develop new ways to predict how long patients with neuroendocrine neoplasms might remain stable without their disease getting worse. This will be done by analyzing measurements from combined scans using both imaging substances. During the study, participants will receive both types of imaging solutions and undergo PET/CT scanning.

Both imaging substances are given as single injections into a vein. 64Cu-DOTATATE attaches to specific receptors found on neuroendocrine tumors, while 18F-FDG helps show how active the tumor cells are. The combination of these two different types of scans provides doctors with more complete information about the tumor’s characteristics and behavior.

The purpose of this study is to determine whether it is possible to perform both imaging methods at the same time to better understand how tumors use energy. During the study, participants will receive two different injectable substances: hyperpolarized [1-13C]pyruvate and Fluor-18-FDG. Both substances will be given through an intravenous injection, and then special images will be taken using a combined PET/MR scanner.

This research will help doctors better understand how tumors process different nutrients and may lead to improved ways of detecting and monitoring cancer. The imaging procedure will be performed once for each participant, and the total dose of each substance has been carefully calculated to ensure safety.

The purpose of the study is to understand the benefits of continuing treatment with somatostatin analogues (a type of medication that helps control hormone-related symptoms) when the disease progresses. The study is divided into two parts: one part looks at the effects of continuing or stopping these medications when patients start a second-line treatment called PRRT (Peptide Receptor Radionuclide Therapy), and the other part examines the effects when patients start a different type of second-line treatment known as targeted therapy. The study aims to see if continuing these medications can help delay the worsening of the disease and improve the quality of life for patients.

Participants in the study will receive either the medication or a placebo, and their progress will be monitored over time. The study will assess how long patients can live without their disease getting worse and how long it takes for their overall health to decline. The study will also look at the overall survival rates, response to treatment, quality of life, and any side effects experienced by the participants. This information will help determine the best approach to managing neuroendocrine tumors when the disease progresses.

The purpose of this study is to explore whether the combination of ramucirumab and dacarbazine can help control the disease in patients with these specific pancreatic tumors. Participants in the study will receive the treatment and be monitored over a period to assess how their disease responds. The study will look at various outcomes, including how well the tumors respond to the treatment, how long patients live without the disease getting worse, and the overall survival of the patients. Additionally, the study will evaluate the side effects of the treatment and its impact on the patients’ quality of life.

Throughout the study, researchers will also conduct additional tests to understand more about the disease and the treatment’s effects. This includes looking at certain proteins and markers in the blood that might predict how well the treatment works. The study aims to provide valuable information that could lead to better treatment options for patients with this type of pancreatic cancer in the future.